NCT01457417 · REGISTRY CONDITION SEARCH

A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE1
Status at capture: COMPLETED
Registry last update: 2016-09-28

The purpose of this trial is to characterize the safety and toxicity of DKN-01 by determining a maximum-tolerated dose and associated dose limiting toxicity. To evaluate the pharmacodynamic response in patients with cancer. To characterize the pharmacokinetic parameters of DKN-01 in cancer patients who are intolerant to standard/approved therapies.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Summary of Total Adverse Events (AE)

→

outcome · POSTED

Summary of Patients With Adverse Events (AE)

→

outcome · POSTED

Pharmacokinetics: Area Under the Concentration - Time Curve (AUC) of DKN-01

→

outcome · POSTED

Pharmacokinetics: Area Under the Concentration - Time Curve (AUC) of DKN-01

→

outcome · POSTED

Pharmacokinetic: Maximum Plasma Concentration (Cmax) of DKN-01

→

outcome · POSTED

Pharmacokinetic: Maximum Plasma Concentration (Cmax) of DKN-01

→

outcome · POSTED

Progression Free Survival (PFS) in Patients Who Are Refractory or Intolerant to Standard/Approved Therapies

→

outcome · POSTED

Overall Survival (OS) in Patients With Relapsed or Refractory NSCLC

→

outcome · POSTED

Objective Response Rate (ORR) in Oncologic Patients Who Are Refractory or Intolerant to Standard/Approved Therapies

→

outcome · POSTED

Objective Response Rate (ORR) in Patients With Relapsed or Refractory Non-small Cell Lung Cancer (NSCLC)

→

outcome · POSTED

Progression Free Survival (PFS) in Patients With Relapsed or Refractory Non-small Cell Lung Cancer (NSCLC)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: Part A: Patients with histological or cytological confirmed multiple myeloma or advanced solid tumors. For multiple myeloma, must have symptomatic myeloma as defined by the International Myeloma Working Group inclusive of measurable serum and/or urine monoclonal protein (M-protein) or for those without elevations they must have measurable increased concentrations of free light chains Part B: Patients with previously treated, histologically confirmed advanced NSCLC with progressive disease requiring therapy Parts A and B: * Refractory or intolerant to all standard/approved therapy(ies) * Patients with solid tumors must have one or more metastatic tumors measurable on computed tomography (CT) scan using Response Evaluation Criteria in Solid Tumors (RECIST) criteria * Radiation for symptomatic lesions outside the central nervous system (CNS) must have been completed at least 2 week prior to study enrollment * Treated brain metastases will be allowed, if they are asymptomatic. Patients must be off corticosteroids for at least 2 week prior to study entry * Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 * Life expectancy of at least 3 months * Ambulatory patients greater than or equal to (≥) 30 years of age * Females with child bearing potential must have a negative serum pregnancy test within 7 days of study entry * Acceptable liver function, renal function, hematologic status * Urinalysis - No clinically significant abnormalities * Acceptable coagulation status: * Prothrombin Time/Partial Thromboplastin Time (PT/PTT) ≤ 1.2 x upper limit of normal (ULN) (unless receiving anticoagulation therapy - eligibility based upon INR) * International Normalization Ratio (INR) ≤ 1.6 (unless receiving anticoagulant therapy) * Receiving warfarin; INR ≤ 3.0 and no active bleeding * For men and women of child-producing potential, the use of effective contraceptive methods during the study and for women 18 months following the last dose of study drug * Available for the study duration and willing to follow procedures * Serum calcium: * Solid tumors only: within normal limits * Multiple myeloma: ≤ 11.5 milligrams per deciliter (mg/dL) Exclusion Criteria: * History of osteonecrosis of the hip or evidence of structural bone abnormalities in the proximal femur on magnetic resonance imaging (MRI) scan considered clinically significant or may impact the interpretation of the scan. Degenerative changes of the hip joint are not exclusionary * Unable to tolerate the confinement/noise of an MRI scanner or have any contraindication for MRI * New York Heart Association Class 3 or 4, cardiac disease, myocardial infarction, unstable arrhythmia, or evidence of ischemia * Have Fridericia-corrected QT interval (QTcF) \> 470 millisecond (msec) (female) or \> 450 (male), or history of congenital long QT syndrome. * Active, uncontrolled bacterial, viral, or fungal infections * Pregnant or nursing women * Radiation therapy, surgery, or chemotherapy, within 1 month prior to study entry * Previously treated with an anti-Dickkopf-related protein 1 (DKK-1) therapy * Significant allergy to a biological pharmaceutical therapy * History of major organ transplant * Had an autologous or allogenic bone marrow transplant, current acute leukemia, colon, prostate, breast or small cell lung cancer, osteoblastic lesions, concomitant disease known to influence calcium metabolism including hyperparathyroidism, hyperthyroidism and/or Paget's disease of bone * Unwillingness / inability to comply with procedures * Known infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C * Serious nonmalignant disease * Receiving other investigational agent or have received other investigational agent within last 30 days or 5 half-lives, whichever is longer * Receiving lithium chloride (LiCl)
healthy Volunteers: false
minimum Age: 30 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
DKN-01: DKN-01 was administered intravenously (IV) once a week over a minimum of 30 minutes and up to a maximum of 2 hours for dose levels of 75 mg, 150 mg and 300 mg. At the 600 mg dose level, DKN-01 was administered by IV on days 1 and 15 of each cycle. PART A - Dose Escalation: Study group of 3 participants were treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation occurred sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching the maximum tolerated dose (MTD) were met or the highest planned dose study group was completed. Cycle 1 defined the dose limiting toxicity (DLT) period that governs dose escalation. The dose escalation method was guided by the incidence of DLTs during the first cycle.
intervention Names
Drug: DKN-01
label
75 milligram (mg) DKN-01 Part A
type
EXPERIMENTAL
description
DKN-01: DKN-01 was administered intravenously (IV) once a week over a minimum of 30 minutes and up to a maximum of 2 hours for dose levels of 75 mg, 150 mg and 300 mg. At the 600 mg dose level, DKN-01 was administered by IV on days 1 and 15 of each cycle. PART A - Dose Escalation: Study group of 3 participants were treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation occurred sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching the maximum tolerated dose (MTD) were met or the highest planned dose study group was completed. Cycle 1 defined the dose limiting toxicity (DLT) period that governs dose escalation. The dose escalation method was guided by the incidence of DLTs during the first cycle.
intervention Names
Drug: DKN-01
label
150 mg DKN-01 Part A
type
EXPERIMENTAL
description
DKN-01: DKN-01 was administered intravenously (IV) once a week over a minimum of 30 minutes and up to a maximum of 2 hours for dose levels of 75 mg, 150 mg and 300 mg. At the 600 mg dose level, DKN-01 was administered by IV on days 1 and 15 of each cycle. PART A - Dose Escalation: Study group of 3 participants were treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation occurred sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching the maximum tolerated dose (MTD) were met or the highest planned dose study group was completed. Cycle 1 defined the dose limiting toxicity (DLT) period that governs dose escalation. The dose escalation method was guided by the incidence of DLTs during the first cycle.
intervention Names
Drug: DKN-01
label
300 mg DKN-01 Part A
type
EXPERIMENTAL
description
DKN-01: DKN-01 was administered intravenously (IV) once a week over a minimum of 30 minutes and up to a maximum of 2 hours for dose levels of 75 mg, 150 mg and 300 mg. At the 600 mg dose level, DKN-01 was administered by IV on days 1 and 15 of each cycle. PART A - Dose Escalation: Study group of 3 participants were treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation occurred sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching the maximum tolerated dose (MTD) were met or the highest planned dose study group was completed. Cycle 1 defined the dose limiting toxicity (DLT) period that governs dose escalation. The dose escalation method was guided by the incidence of DLTs during the first cycle.
intervention Names
Drug: DKN-01
label
600 mg DKN-01 Part A
type
EXPERIMENTAL
description
Dose Confirmation: Once the MTD had been established or the highest planned dose level completed, 300 mg of DKN-01 was administered as IV on days 1 and 15 of every 28 day cycle.
intervention Names
Drug: DKN-01
label
300 mg DKN-01 Part B
type
EXPERIMENTAL

interventions

arm Group Labels
150 mg DKN-01 Part A
300 mg DKN-01 Part A
300 mg DKN-01 Part B
600 mg DKN-01 Part A
75 milligram (mg) DKN-01 Part A
description
DKN-01 will be administered intravenously (IV) once a week over 30 minutes (min) and 2 hours (max) for 75, 150 and 300 mg. At 600 mg, DKN-01 will be administered by IV on days 1 and 15 of each cycle. PART A - Dose Escalation: 3 participants will be treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation will occur sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching maximum tolerated dose (MTD) are met (or highest planned dose study group is completed). Cycle 1 will define the dose limiting toxicity (DLT) that governs dose escalation. PART B - Dose Confirmation: Once the MTD is established (or the highest planned dose level), 300 mg of DKN-01 will be administered IV on days 1 and 15 of every 28 day cycle.
name
DKN-01
other Names
Formerly LY2812176
type
DRUG

Study design

allocation

NON_RANDOMIZED

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 32
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Total Adverse Events (AE), total treatment emergent adverse events (TEAE), total Serious Adverse Events (SAE), and total dose-limiting toxicity (DLT) for both Parts A and B.
measure
Summary of Total Adverse Events (AE)
time Frame
Baseline to study completion (approximately 3 months)
description
Number of patients who had Adverse Events (AE) including treatment related treatment emergent adverse events (TEAE), Common Toxicity Criteria for Adverse Effects (CTCAE), and Serious Adverse Events (SAE) for both Parts A and B. Severity was coded to NCI CTCAE version 4.02. For maximum severity and relationship, patients were counted only once in the most severe or most related category.
measure
Summary of Patients With Adverse Events (AE)
time Frame
Baseline to study completion (approximately 3 months)
description
For Part B only. The distribution of PFS was estimated using the Kaplan-Meier (KM) method. PFS was defined as the time from the date of signed informed consent to the first date of objectively determined progressive disease (Progression is defined by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) and International Multiple Myeloma Working Group (IMWG)) or death from any cause. For patients who were still alive at the time of analysis (ie, data cut-off date) and without evidence of tumor progression, PFS was censored at the date of the most recent objective progression-free observation.
measure
Progression Free Survival (PFS) in Patients With Relapsed or Refractory Non-small Cell Lung Cancer (NSCLC)
time Frame
Time from the date of signed informed consent to the first date of objectively determined progressive disease or death from any cause

secondary Outcomes

description
Area under the DKN-01 serum concentration-time profile curve during the dosing interval (AUC0-tau) after the first and fourth infusion for both Parts A and B. Cycle 1 Day 1 included once per week (QW) dosing groups and every two weeks (Q2W) dosing groups.
measure
Pharmacokinetics: Area Under the Concentration - Time Curve (AUC) of DKN-01
time Frame
Cycle 1 Day 1 (first dose, all groups)
description
Area under the DKN-01 serum concentration-time profile curve during the dosing interval (AUC0-tau) after the first and fourth infusion for both Parts A and B. Cycle 1 day 22 included only QW dosing groups.
measure
Pharmacokinetics: Area Under the Concentration - Time Curve (AUC) of DKN-01
time Frame
Cycle 1 Day 22 (Fourth Dose for QW)
description
Peak DKN-01 serum concentration (Cmax) after the first and fourth infusion on Cycle 1 Weeks 1 and 4, for both Parts A and B. Cycle 1 Day 1 included once per week (QW) dosing groups and every two weeks (Q2W) dosing groups.
measure
Pharmacokinetic: Maximum Plasma Concentration (Cmax) of DKN-01
time Frame
Cycle 1 Day 1 (first dose, all groups)
description
Peak DKN-01 serum concentration (Cmax) after the fourth infusion on Cycle 1 Weeks 1 and 4, for both Parts A and B. Cycle 1 day 22 included only QW dosing groups.
measure
Pharmacokinetic: Maximum Plasma Concentration (Cmax) of DKN-01
time Frame
Cycle 1 Day 22 (Fourth dose for QW groups)
description
For both Parts A and B. PFS was defined as the time from the date of signed informed consent to the first date of objectively determined progressive disease (Progression is defined by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) and International Multiple Myeloma Working Group (IMWG)) or death from any cause. For patients who were still alive at the time of analysis (i.e, data cut-off date) and without evidence of tumor progression, PFS was censored at the date of the most recent objective progression-free observation.
measure
Progression Free Survival (PFS) in Patients Who Are Refractory or Intolerant to Standard/Approved Therapies
time Frame
Time from the date of signed informed consent to the first date of objectively determined progressive disease or death from any cause
description
For Part B only. OS was defined as the time from the date of signed informed consent to the date of death from any cause. For patients who were still alive as of the data cut-off date, OS time was censored on the date of the patient's last contact (last contact for patients in post-discontinuation was the last date of contact in long-term follow-up eCRF).
measure
Overall Survival (OS) in Patients With Relapsed or Refractory NSCLC
time Frame
Time from the date of signed informed consent to the date of death from any cause
description
For both Parts A and B. Objective response rate is defined as the number of patients with overall best response of complete response (CR) or partial response (PR)
measure
Objective Response Rate (ORR) in Oncologic Patients Who Are Refractory or Intolerant to Standard/Approved Therapies
time Frame
Part A: Every 2 months; Part B: after 1 month and every two cycles thereafter
description
FAS : For both Parts A and B. Objective response rate is defined as the number of patients with overall best response of complete response (CR) or partial response (PR)
measure
Objective Response Rate (ORR) in Patients With Relapsed or Refractory Non-small Cell Lung Cancer (NSCLC)
time Frame
Part A: Every 2 months; Part B: after 1 month and every two cycles thereafter

Full study description

brief Summary: The purpose of this trial is to characterize the safety and toxicity of DKN-01 by determining a maximum-tolerated dose and associated dose limiting toxicity. To evaluate the pharmacodynamic response in patients with cancer. To characterize the pharmacokinetic parameters of DKN-01 in cancer patients who are intolerant to standard/approved therapies.
detailed Description: Part A of this trial consists of 4 treatment arms of DKN-01. It is a dose escalation study in patients with multiple myeloma or advanced solid tumors. Patients must be refractory or intolerant to all standard/approved therapy(ies). At each dose level, 3 subjects will be treated. If none of the 3 subjects develop a dose limiting toxicity after a minimum of 4 weeks of treatment, subsequent dose escalation will proceed according to the same schedule. Part B consists of dose confirmation in patients with NSCLC. Patients must be refractory or intolerant to all standard/approved therapy(ies). Approximately 15 patients may be enrolled in Part B.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-fc62f186cf55d8eb7dd9
requested nct id
NCT01457417
primary nct id
NCT01457417
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
a0f819bc3ec850077d370d0015a93e7a5df4f01b4d2acf203544f49836bd9307
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-fc62f186cf55d8eb7dd9
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01457417
occurrences
context exact
NCT01457417
end
11
exact text
NCT01457417
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/298/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
0e596d384742306f6c9117e88e384b04d1d72695009b7459029a220f7b4aa066
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice